Merge Labs is developing an ultrasound-based brain-computer interface that avoids direct electrode implantation, instead using functional ultrasound imaging combined with engineered molecular reporters — specialized proteins that amplify neural activity signatures detectable by ultrasound from outside the skull. Resolution on the order of 100 microns with a field of view spanning from cortical surface to deep brain center. Co-founded by Mikhail Shapiro, Tyson Aflalo, Sumner Norman, Alex Blania, Sandro Herbig, and Sam Altman. A spinoff of Forest Neurotech, a nonprofit studying miniaturized ultrasound in a UK safety trial. Launched January 2026 with $252M in seed funding at $850M valuation, led by OpenAI.
This device does not have a current FDA designation. It may be a research tool, preclinical device, or consumer product not subject to FDA medical device regulation.
FDA Device Regulatory Guidance ↗